Glimepiride USP and Metformin Hydrochloride USP
Composition: Each Film Coated Tablet ContainsGlimepiride USP 1 mg and Metformin HydrochlorideUSP 500 mg as Extended Release.
Indication: This combination is indicated as an adjunctto diet and exercise to improve glycemic control inadults with type 2 diabetes mellitus when treatment withboth Glimepiride and Metformin is appropriate or incases where Glimepiride/Metformin mono-therapy doesnot result in adequate glycemic control.
Dosage & administration: The initial recommendeddose of Glimepiride and Metformin combination tabletGlimepiride 1 mg and Metformin HCL 500 mg XR tabletonce daily with breakfast or first main meal of the day.Starting dose for patients inadequately controlled on
Glimepiride or Metformin monotherapy is Limpet-M 1once daily, and gradually titrated after assessing thetherapeutic response. Titration: The daily dose must betitrated in increments of 1 tablet. The maximumrecommended dose per day is 8 mg Glimepiride and2000 mg Metformin. When switching from combinationtherapy of Glimepiride plus Metformin to separatetablets, Glimepiride and Metformin should beadministered separately on the basis of dosagecurrently being taken. When Glimepiride and Metformincombination tablet is used in combination or with insulin,a lower dose of the Glimepiride or insulin may berequired to reduce the risk of hypoglycemia. Or, asdirected by the registered physician.
Use in pregnancy and lactation: The use of thiscombination is not recommended in pregnancy &lactation.
Packing: Each box contains 3 x 7's tablets in blisterpack.